← Leaderboards
Anita Bellail
Hb Therapeutics, Inc.
$2,437,226
Attributed
$3,769,972
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,769,972 · 3
By mechanism
R44$1,999,119 · 1
R01$1,470,853 · 1
R43$300,000 · 1
Top collaborators
- Chunhai Charlie Hao2 shared
- Ho Yin Lo2 shared
Others in their field
Other Emerging Leaders on “Lead”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
Research focus
LeadModificationTreatment EfficacyUbiquitinPharmacotherapyAntineoplastic AgentsProteinsToxicologyUbiquitinationPharmaceutical PreparationsSmall MoleculeDiagnosisAnticancer ActivityBinding ProteinsBindingMediatingMetabolicMetastatic ColorectalCrispr/Cas TechnologyNuclear Magnetic ResonanceEffective TherapyGenome-WideHuman DiseaseOrganoids
Grant awards (7)
Targeting SUMO1 degradation for advanced colon cancer therapy$373,036
R01 · FY2025 · CA · contact PI
Targeting SUMO1 degradation for advanced colon cancer therapy$354,509
R01 · FY2024 · CA · contact PI
Development of SUMO1 small molecule degraders as the first-in-class anticancerdrugs for metastatic colorectal cancer$979,536
R44 · FY2023 · CA · contact PI
Targeting SUMO1 degradation for advanced colon cancer therapy$373,955
R01 · FY2023 · CA · contact PI
Development of SUMO1 small molecule degraders as the first-in-class anticancerdrugs for metastatic colorectal cancer$1,019,583
R44 · FY2022 · CA · contact PI
Targeting SUMO1 degradation for advanced colon cancer therapy$369,353
R01 · FY2022 · CA · contact PI
Development of Small Molecule SUMO1 Inhibitors for Treatment of Glioblastoma$300,000
R43 · FY2018 · CA · contact PI